



43

**Patent**

Docket Number: AM-00102.P.1-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	)	
	)	
Efimov et al.	)	Examiner: To be determined
	)	
Application No.: To be determined	)	Art Unit: To be determined
	)	
Filed: Herewith	)	
	)	
For: OLIGONUCLEOTIDE	)	
ANALOGUES, METHODS OF	)	
SYNTHESIS AND METHODS	)	
OF USE	)	
	)	
<hr/>		
Assistant Commissioner for Patents		
Washington D.C. 20231		

Sir:

STATEMENT UNDER 37 C.F.R. 1.821 through 1.825

In accordance with the requirements under 37 C.F.R. 1.821 through 1.825 for patent applications containing nucleotide sequence and/or amino acid sequence disclosures, Applicants submit herewith a written Sequence Listing and corresponding Substitute Computer Readable Form for the above-identified application. The information recorded in the Substitute Computer Readable Form is identical to the written Sequence Listing and are identical to the information provided in the application as originally filed. Apparently, the Computer Readable Form was damaged in transit to the USPTO causing improper reading thereof. Thus, no new matter has been added.



Please apply any charges not covered, or any credits, to **Deposit Account 501321** in the name of **David R. Preston & Associates** having **Customer No.: 24232**.

Date:

July 7, 2001

Respectfully submitted,

David R. Preston  
Reg. No. 38,710

David R. Preston & Associates  
11404 Sorrento Valley Road  
Suite 104  
San Diego, CA 92121

Telephone: 858.450.1388  
Facsimile: 858.450.2188